1 412

Cited 2 times in

Salvage chemotherapy with docetaxel and epirubicin for Advanced/Metastatic gastric cancer

 Jae Yun Lim  ;  Jae Yong Cho  ;  Yong Han Paik  ;  Dong Ki Lee  ;  Sang In Lee  ;  Hyo Jin Park  ;  Se Joon Lee  ;  Kwan Sik Lee  ;  Dong Sup Yoon  ;  Seung Ho Choi 
 ONCOLOGY, Vol.73(1-2) : 2-8, 2008 
Journal Title
Issue Date
Adenocarcinoma/drug therapy* ; Adenocarcinoma/secondary ; Adult ; Aged ; Antibiotics, Antineoplastic/administration & dosage ; Antibiotics, Antineoplastic/adverse effects ; Antineoplastic Agents, Phytogenic/administration & dosage ; Antineoplastic Agents, Phytogenic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use* ; Disease Progression ; Disease-Free Survival ; Docetaxel ; Drug Administration Schedule ; Epirubicin/administration & dosage ; Epirubicin/adverse effects ; Female ; Fluorouracil/administration & dosage ; Hematologic Diseases/chemically induced ; Humans ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Patient Selection ; Platinum Compounds/administration & dosage ; Salvage Therapy/methods* ; Severity of Illness Index ; Stomach Neoplasms/drug therapy* ; Stomach Neoplasms/pathology* ; Taxoids/administration & dosage ; Taxoids/adverse effects ; Treatment Outcome
Gastric cancer ; Docetaxel chemotherapy
Background: We conducted a phase II study to assess the efficacy and tolerability of docetaxel and epirubicin as salvage chemotherapy in advanced/metastatic gastric cancer patients with documented progression after 5-fluorouracil/platinum-based combination chemotherapy. Methods: Docetaxel 75 mg/m2 and epirubicin 50 mg/m2 were administered on days 1 and 2, respectively, every 3 weeks. Treatment continued until progression of disease or until a life-threatening adverse event occurred. The primary objectives of this study were to evaluate the safety profile and response rate to this treatment regimen. Results: Thirty-four patients were enrolled in the study. Twenty-six patients had locally advanced or metastatic disease at the time of diagnosis, and 8 patients had recurrent disease after surgical resection of the primary tumor. A total of 157 chemotherapy cycles were administered. Seven (21.8%) patients had a partial response and 12 (37.5%) patients had stable disease. The median time to progression and overall survival were 4.1 and 13.4 months, respectively. Grade III/IV hematologic toxicities included neutropenia in 16 patients (47%) and febrile neutropenia in 8 patients (24%). Nonhematologic toxicities were rare. Conclusion: A combination of chemotherapy with docetaxel and epirubicin showed moderate activity as salvage treatment in advanced/metastatic gastric cancer, especially in patients who had responded to prior chemotherapy.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers
Yonsei Authors
Park, Hyo Jin(박효진) ORCID logo https://orcid.org/0000-0003-4814-8330
Paik, Yong Han(백용한)
Yoon, Dong Sup(윤동섭) ORCID logo https://orcid.org/0000-0001-6444-9606
Lee, Kwan Sik(이관식) ORCID logo https://orcid.org/0000-0002-3672-1198
Lee, Dong Ki(이동기) ORCID logo https://orcid.org/0000-0002-0048-9112
Lee, Sang In(이상인)
Lee, Se Joon(이세준) ORCID logo https://orcid.org/0000-0002-2695-2670
Lim, Jae Yun(임재윤)
Cho, Jae Yong(조재용) ORCID logo https://orcid.org/0000-0002-0926-1819
Choi, Seung Ho(최승호) ORCID logo https://orcid.org/0000-0002-9872-3594
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.